Analytical Data
-
基因名
TOP3
- Application
-
别名
TOP3A; DNA topoisomerase III alpha
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q13472
-
表达区间
Lys35~Ser179
-
分子量
19kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Recombinant proteins are crucial tools in biotechnology and molecular biology, serving diverse applications ranging from therapeutic agents to industrial enzymes. Among the top three recombinant proteins, insulin, monoclonal antibodies, and erythropoietin stand out due to their significant impact on medicine and healthcare. Insulin, first synthesized in the 1920s, revolutionized diabetes treatment, highlighting the potential of recombinant DNA technology to produce therapeutic proteins safely and in large quantities. Monoclonal antibodies, developed in the 1970s, have transformed diagnostics and treatment for various conditions, including cancers and autoimmune diseases, through targeted therapies. Erythropoietin, initially isolated from the kidneys, plays a vital role in regulating red blood cell production and has been pivotal in treating anemia, particularly in patients with chronic kidney disease. The development of these proteins illustrates not only the advancements in genetic engineering but also the growing need for innovative treatments driven by recombinant technology. Understanding the mechanisms of protein expression and purification techniques has further fueled research, making recombinant proteins essential in drug development, therapeutic applications, and fundamental biological research, thereby underscoring their significance in modern science and medicine.
